Pharmaceutical Companies Sign $180 Million Deal (ENDP, BDSI)
Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP has signed a deal with BioDelivery Sciences International Inc. (NASDAQ: BDSI) under which Endo will license and pay royalties on a pain treatment drug and delivery system developed by BioDelivery. The agreement will be…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP has signed a deal with BioDelivery Sciences International Inc. (NASDAQ: BDSI) under which Endo will license and pay royalties on a pain treatment drug and delivery system developed by BioDelivery. The agreement will be worth up to $180 million to BioDelivery.
The deal includes an upfront payment of $30 million to BioDelivery and a further $150 million as certain milestones are reached. The licensed drug, known as BEMA Buprenorphine, is currently in Phase 3 trials for the treatment of moderate to severe chronic pain.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
